Lakvinimod (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lakvinimod" in Serbian language version.

refsWebsite

Global rank Serbian rank

4^th place

8^th place

2^nd place

4^th place

149^th place

283^rd place

low place

doi.org

Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
Comi G; Pulizzi A; Rovaris M; et al. (2008). „Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study”. Lancet. 371 (9630): 2085—92. PMID 18572078. doi:10.1016/S0140-6736(08)60918-6.
Polman C; Barkhof F; Sandberg-Wollheim M; et al. (2005). „Treatment with laquinimod reduces development of active MRI lesions in relapsing MS”. Neurology. 64 (6): 987—91. PMID 15781813. doi:10.1212/01.WNL.0000154520.48391.69.
Keegan BM, Weinshenker BG (2008). „Laquinimod, a new oral drug for multiple sclerosis”. Lancet. 371 (9630): 2059—60. PMID 18572062. doi:10.1016/S0140-6736(08)60894-6.

Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
Tan IL; Lycklama à Nijeholt GJ; Polman CH; et al. (2000). „Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials”. Mult Scler. 6 (2): 99—104. PMID 10773855.
Comi G; Pulizzi A; Rovaris M; et al. (2008). „Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study”. Lancet. 371 (9630): 2085—92. PMID 18572078. doi:10.1016/S0140-6736(08)60918-6.
Polman C; Barkhof F; Sandberg-Wollheim M; et al. (2005). „Treatment with laquinimod reduces development of active MRI lesions in relapsing MS”. Neurology. 64 (6): 987—91. PMID 15781813. doi:10.1212/01.WNL.0000154520.48391.69.
Keegan BM, Weinshenker BG (2008). „Laquinimod, a new oral drug for multiple sclerosis”. Lancet. 371 (9630): 2059—60. PMID 18572062. doi:10.1016/S0140-6736(08)60894-6.